Navigation Links
Kidney function discovery sheds light on genetic complexity of disease
Date:11/26/2008

To find a cure for cancer, haemophilia and other diseases, researchers need to be looking for complex, interacting genetic factors, according to the authors of a new study.

A new study, published in the Journal of Clinical Investigation by researchers at the Centenary Institute, Royal Prince Alfred Hospital (RPA) and The Australian National University (ANU), has exposed a greater level of genetic complexity for diseases than was originally thought.

The researchers looked at two disorders of kidney function - iminoglycinuria and hyperglycinuria. These disorders, first described 50 years ago, are conditions where large amounts of individual amino acids (the building blocks of proteins in our body) are wasted by the kidney.

Professor John Rasko, Head, Gene and Stem Cell Therapy program at Centenary Institute and Cell and Molecular Therapies at RPA, says although up to one in every thousand babies has this disorder at birth, it usually resolves in the first year of life. For those individuals in whom it continues to occur, it is generally thought not to cause medical problems but previous cases have been linked to high blood pressure, kidney stones, deafness and problems in the brain.

"Iminoglycinuria was observed to occur in families and the pattern of inheritance suggested that the cause might be due to an inherited abnormality of a specific pump on the surface of kidney cells," Professor Rasko explains.

The teams from Centenary Institute, RPA and ANU have now unravelled the genetic explanation by showing that not one, but up to four different pumps present in the kidney determine whether or not this particular abnormality occurs.

"The study demonstrates that in some cases mutations occur only in one gene, while in other cases mutations in two or even three different genes are observed, and that the disorders can arise due to mutations in a group of genes carrying out related functions," says Profes
'/>"/>

Contact: Erin Sharp
e.sharp@centenary.org.au
029-565-6118
Research Australia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Diet support helps chronic kidney patients
2. Genetic breakthrough offers promise in tackling kidney tumors
3. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
4. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
5. Gaining a better understanding of kidney diseases
6. High blood pressure takes big toll on small filtering units of the kidney
7. Scientists identify cell changes leading to impaired artificial kidney function
8. Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
9. Device helps patients survive, regain function til transplant
10. Specific brain protein required for nerve cell connections to form and function
11. Systems Biology poised to revolutionize the understanding of cell function and disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a complex cocktail of poisonous peptides that immobilize animal ... this cocktail damage only insects, which is why a ... a safe and ecologically sound pesticide. Prof. Michael ... has isolated the genetic sequences for important neurotoxins in ...
... the lichen Phylloblastia fortuita , new to the Iberian ... Phylloblastia dispersa , is also a new entry for ... outside the tropics. Foliicolous lichens, symbiosis between fungi ... and their presence in environments such as the Iberian Peninsula, ...
... COLUMBUS, Ohio Blocking the function of an enzyme in ... prevent nerve cells from dying after a stroke, new research ... found that the tocotrienol form of vitamin E, an alternative ... fatty acids that eventually kill neurons. The Ohio State ...
Cached Biology News:A deadly scorpion provides a safe pesticide 2A new species of lichen discovered in the Iberian Peninsula 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3
(Date:7/24/2015)... July 24, 2015  Champions Oncology (OTC-BB: CSBR), a ... and services to personalize the development and use of ... and operational results for the fourth quarter and fiscal ... 28, 2015, before market open. The company ... that day at 9:00 a.m. EDT (6:00 a.m. PDT). ...
(Date:7/24/2015)... -- The global next generation sequencing ... by 2022, growing at an estimated CAGR of 40.1% ... by Grand View Research, Inc. Development of faster, more ... significant reduction in cost of sequencing one base pair. ... of next generation sequencing throughout the forecast period. Revenue ...
(Date:7/23/2015)... LOS ANGELES , July 23, 2015 ImmunoCellular ... plans to report financial results for the second quarter 2015 ... hold a conference call and webcast on that day at ... results and provide a business update. The call will be ...   , , , LIVE CALL: ...
(Date:7/23/2015)... ... July 23, 2015 , ... One hundred years ago ... 1915 National Model Aeroplane Competition, with hopes of winning the Henry S. Villard Trophy. ... centennial. , Participants will have the opportunity to build a Free Flight fantasy club ...
Breaking Biology Technology:Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 2Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 3Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 4Next Generation Sequencing (NGS) Market To Reach $27.8 Billion By 2022: Grand View Research, Inc. 5ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2
... , RICHMOND, Va., July 31 Insmed Inc. ... that it will host a conference call on Thursday, August ... for the second quarter 2009. Insmed intends to issue ... on August 13(th). , , To participate ...
... TOKYO, July 31 R-Tech Ueno, Ltd. announced on July ... board of directors held on the day and determined the R&D ... to actively strengthen R&D in the ophthalmologic & dermatological fields that ... with external entities. , , 1. Development code ...
... , , , ... ANDS ) today announced finalization of the protocol for the ... ribavirin in hepatitis C patients. Allowance of the protocol has been ... dosing is expected to commence within the next several weeks. , ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
HOXC11 Antibody...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: